Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream NEW YORK, Jan. 11, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: With each new study, the horizon of GLP-1’s therapeutic potential expands, painting a vibrant picture of a future where a single molecule could tackle a multitude of ...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 60+ brands within the @ (), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs,” please visi...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Can Diabetes, Weight-Loss Drugs Get Even Better?” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: It shouldn’t be surprising that analysts at Markets and Research estimate the global diabetes drug market at $63.1 billion in 2021 on its way to $82.93 billion in 2027, while th...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 60+ brands within the @ (), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Can Diabetes, Weight-Loss Drugs Get Even Better?”,please visit: The prest...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “The Power of Science to Stop a Killer.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: In its 2021 industry report, estimated the global anti-hypertensive drugs market at $24.17 billion in 2020 on its way to reach $27.81 billion in 2025. All told, hypertension costs the country on average ann...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Developing Powerful Tech to Treat Hypertension NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 50+ trusted brands within the (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “The Power of Science to Stop a Killer,” please visit: Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More ...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Nicotine Surges as Smoking Sags.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: The fact remains that an estimated 1.1 billion people smoked cigarettes in 2019. According to stats from the World Health Organization, a stunning 780 million people said they want to quit. As a result, people look to a multitud...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 50+ trusted brands within the (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Nicotine Surges as Smoking Sags,” please visit: Seems like yesterday people were smoking cigarettes everywhere; many people still have memories of Grandpa puffing on his Ca...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: The Silent Killer Making Loud Noise for Investors.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: The market is certainly worth entering. Consider that Reportlinker.com estimates the global anti-hypertensive drugs market to be $24.37 billion in 2021 and growing 3.4% an...
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Throw Hat into Hypertension Ring with Proprietary Drug-Delivery System NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 50+ trusted brands within the (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Hypertension: The Silent Killer Making Loud Noise for Investors,” please visit: Hypertension, or high blood pressure, is rampant in America. An estimat...
Lexaria Bioscience Corp. (NASDAQ: LEXX) on Forefront of Exciting Hypertension Innovation NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space.” To hear the AudioPressRelease, please visit: To view the full editorial, please visit: Controlling blood pressure is essential to health. High blood pressure is a primary or contributing cause of death in almost 500,000 deaths a year, and...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Leads the Way in Innovating Hypertension Treatment NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- via — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by ("NNW"), one of 50+ trusted brands within the (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space,” please visit: One of the most pervasive diseases in first-world count...
DGAP-News: Lexaria Bioscience Corp. / Key word(s): Agreement Lexaria Bioscience Corp.: Lexaria Bioscience announces R&D agreement with British American Tobacco 01.09.2020 / 07:47 The issuer is solely responsible for the content of this announcement. Lexaria Bioscience announces R&D agreement with British American Tobacco Kelowna, British Columbia- August 31, 2020 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered a research and development ("R&D") framework agree...
DGAP-News: Lexaria Bioscience Corp. / Key word(s): Miscellaneous Altria and Lexaria Conclude Phase I Research and Development Program 16.07.2020 / 12:15 The issuer is solely responsible for the content of this announcement. Altria and Lexaria Conclude Phase I Research and Development Program R&D Program Utilized Lexaria's Patented DehydraTECHTM Technology for Oral Nicotine Delivery Conclusion of Phase I allows for additional phased private financings up to a further US$11 million from Altria KELOWNA, BC / ACCESSWIRE / July 16, 2020 / Lexaria Bioscience Corp. (OTCQX:...
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Featured in NetworkNewsAudio Publication Discussing Innovative Drug-Delivery Discovery NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – announces the availability of a NetworkNewsAudio publication titled, “Innovative Drug-Delivery Systems Benefit Patients and Businesses.” To hear the NetworkNewsWire Audio version, visit: To read the full editorial, visit: Drugs play an essential role in treating anything from a mild headache to life-threatening disease — and everything in between. While effectiven...
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Featured in NetworkNewsWire Publication Reporting on Momentous Advances in Drug-Delivery Innovation NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — today announces its placement in an editorial published by ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full publication, titled “Innovative Drug-Delivery Systems Benefit Patients and Businesses,” visit: The search for innovation is vital in any sector but particularly so in health and medicine. While existing pro...
Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast on Dramatic Results of CBD Delivery System Study NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- via CannabisNewsAudio – today announces the availability of an audio press release titled, “Dramatically Improved Delivery Systems Promise More Effective Cannabis Treatments.” To hear the CannabisNewsAudio version, visit: . To read the full editorial, visit: . A biotech company based in British Columbia, is currently focusing on its proprietary DehydraTECH(TM) technology. This unique technology has been developed to make me...
Lexaria Bioscience Corp. Featured in CannabisNewsWire Publication Describing Dramatic CBD Delivery System Improvements NEW YORK, June 12, 2019 (GLOBE NEWSWIRE) -- via CannabisNewsWire – today announces its placement in an editorial published by ("CNW"), a multifaceted financial news and publishing company for private and public entities in the cannabis industry. To view the full publication, titled “Dramatically Improved Delivery Systems Promise More Effective Cannabis Treatments,” please visit: The popularity of cannabinoid products — those containing active ingredients from cannabi...
Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast Touting Impact of Technology on CBD Edible Space NEW YORK, May 31, 2019 (GLOBE NEWSWIRE) -- via CannabisNewsAudio – today announces the availability of a CannabisNewsAudio Broadcast titled, “Disruptive CBD Delivery Technology Could Revolutionize World of Cannabis Consumer Products, Edibles.” To hear the CannabisNewsAudio version, visit: . To read the full editorial, visit: . Consider what [’s DehydraTECH] technology could mean for the CBD edibles space. At 15 minutes, the DehydraTECH formulation achieved 475% higher conc...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.